Use of botulinum toxin injection in 17 children with spastic cerebral palsy

Pediatric Neurology

Volumn 18, Issue 2, 1998, Pages 124-131

  Wong, Virginia ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADOLESCENT; ARTICLE; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; JOINT MOBILITY; MALE; MOBILIZATION; PRIORITY JOURNAL; SPASTICITY; TREATMENT OUTCOME;

EID: 0032007345     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-8994(97)00164-1     Document Type: Article

References (38)

1. [1] Young RR, Delwaide PJ. Drug therapy in spasticity. N Engl J Med 1981;304:96-9.
2. [2] Carpenter EB, Seitz DG. Intramuscular alcohol as an aid in management of spastic cerebral palsy. Dev Med Child Neurol 1980;22: 497-501.
3. [3] Carpenter EB. Role of nerve blocks in the foot and ankle in cerebral palsy: Therapeutic and diagnostic. Foot Ankle 1983;4:164-6.
4. [4] Tardieu G, Tardieu C. Hariga J, Gagnard L. Treatment of spasticity by injection of dilute alcohol at the motor point or by epidural route: Clinical extension of an experiment on the decerebrate cat. Dev Med Child Neurol 1968;10:555-68.
5. [5] Silver RL, Rang M, Chan J, de la Garza J. Adductor release in nonambulant children with cerebral palsy. J Pediatr Orthop 1985;5: 672-7.
6. [6] Bleck EE. Goals, treatment and management. In: Bleck EE, ed. Orthopaedic management in cerebral palsy. Philadelphia: J.B. Lippincott, 1987:142-212.
7. [7] Albright AL, Cevi A, Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA 1991;265:1418-22.
8. [8] Peacock WJ, Arens LJ, Berman B. Cerebral palsy spasticity: Selective posterior rhizotomy. Pediatr Neurosci 1987;13:61-6.
9. [9] Peacock WJ, Staudt LA. Functional outcomes following selective posterior rhizotomy in children with cerebral palsy. J Neurosurg 1991;74:380-5.
10. [10] Greene WB, Dietz FR, Goldberg MJ, Gross RH, Miller F, Sussman MD. Rapid progression of hip subluxation in cerebral palsy following selective posterior rhizotomy. J Pediatr Orthop 1991;11:494-7.
11. [11] American Academy of Neurology. Assessment: The clinical usefulness of botulinum toxin-A in treating neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1990;40:1332-6.
12. [12] American Academy of Otolaryngology. Head and neck surgery policy statement: Botox for spasmodic dysphonia. AAO-HNS Bull 1990;9:8.
13. [13] Beradelli AL, Mercuri B, Priori A. Botulinum toxin for facial-oral-mandibular spasms and bruxism. In: Jankovic J, Hallett M, eds. Therapy with botulinum toxin. New York: Marcel Dekker. 1994: 299-306.
14. [14] Cruz OA, Flynn JT. Strabismus: Other therapies. In: Jankovic J. Hallet M. eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994:377-86.
15. [15] Magoon EH. Clinical use of botulinum toxin: Clinical trials for strabismus. In: Jankovic J, Hallet M. eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994:371-6.
16. [16] National Institutes of Health Consensus Developmental Conference. Consensus statement: Clinical use of botulinum toxin. Arch Neurol 1991;48:1294-8.
17. [17] Rosenfield DB. Clinical aspects of speech motor compromise. In: Jankovic J, Hallet M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994:397-419.
18. [18] Schantz EJ, Johnson EA. Preparation and characterization of botulinum toxin type A for human treatment. In: Jankovic J, Hallet M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994: 41-9.
19. [19] Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 1981;79:734-70.
20. [20] Snow BJ, Tsui JKC, Bhatl MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: A double-blind study. Ann Neurol 1990:28:512-5.
21. [21] Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994;36:386-96.
22. [22] Koman LA, Mooney JF, Smith B, Goodman A, Mulvaney T, Management of cerebral palsy with botulinum-A toxin: Preliminary investigation. J Pediatr Orthop 1993;13:489-95.
23. [23] Koman LA, Mooney JF, Smith BP. Botulinum toxin: Potential role in the management of cerebral palsy during childhood. In: Jankovic J, Hallet M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994:511-22.
24. [24] Koman LA, Mooney JF, Smith B, Goodman A, Mulvaney T. Management of spasticity in cerebral palsy with Botulinum-A toxin: Report of a preliminary, randomized double-blind trial. J Pediatr Orthop 1994;14:299-303.
25. [25] Cosgrove AP, Graham HK. Botulinum toxin a prevents the development of contractures in the hereditary spastic mouse. Dev Med Child Neurol 1994;36:379-85.
26. [26] Calderon-Gonzalex Z, Calderson-Sepulveda R, Rincon-Reyes M. Garcia-Ramirez J, Mino-Arango E. Botulinum toxin A in management of cerebral palsy. Pediatr Neurol 1994;10:284-8.
27. [27] Denislic M. Meh D. Botulism toxin in the treatment of cerebral palsy. Neuropediatrics 1995;26:249-52.
28. [28] Gooch JL, Sandell TV. Botulism toxin for spasticity and athetosis in children with cerebral palsy. Arch Phys Med Rehabil 1996:77:508-11.
29. [29] Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964;192:540-2.
30. [30] Hoffer MM, Feiwell E, Perry R, Perry J, Bonnett C. Functional ambulation in children with myelomeningocele. J Bone Joint Surg [Am] 1973;55:137-48.
31. [31] Duchen LW, Strich SJ. The effects of botulinum toxin on the pattern of innervation of skeletal muscle in the mouse. Q J Exp Physiol 1968;53:84-9.
32. [32] Kao I, Drachman DB, Price DL. Botulinum toxin: Mechanism of presynaptic blockade. Science 1976;193:1256-8.
33. [33] Sellin LC. The action of botulinum toxin at the neuromuscular junction. Med Biol 1981;59:11-20.
34. [34] Dolly JO, Black J, Williams RS, Melling J. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature 1984;307:457-60.
35. [35] Melling J. Hambleton P, Shone CC. Clostridium botulinum toxins: Nature and preparation for clinical use. Eye 1988;2:16-23.
36. [36] Coffield KA, Considine RV, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallet M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994:3-13.
37. [37] Borodic GE, Ferrante RJ, Pearce LB, Alderson K. Pharmacology and histology of the therapeutic application of botulinum toxin. In: Jankovic J, Hallet M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994:119-57.
38. [38] Zuber M, Sebald M, Bathien N, Recondo J, Rondot P. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: Frequency and significance. Neurology 1993;43:1715-18.